Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 1
2000 2
2001 1
2002 2
2003 1
2004 1
2005 4
2006 2
2007 2
2008 4
2009 3
2010 7
2011 4
2012 3
2013 4
2014 4
2015 14
2016 12
2017 7
2018 8
2019 10
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31662564

84 results

Results by year

Filters applied: . Clear all
Page 1
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Yamada Y, et al. Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Lancet Oncol. 2013. PMID: 24225157 Clinical Trial.
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, Tsuji A, Nakajima TE, Gotoh M, Machida N, Bando H, Esaki T, Emi Y, Sekikawa T, Matsumoto S, Takeuchi M, Boku N, Baba H, Hyodo I. Hironaka S, et al. Lancet Oncol. 2016 Jan;17(1):99-108. doi: 10.1016/S1470-2045(15)00410-6. Epub 2015 Nov 28. Lancet Oncol. 2016. PMID: 26640036 Clinical Trial.
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N. Yamazaki K, et al. Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10. Cancer Chemother Pharmacol. 2015. PMID: 25575764 Clinical Trial.
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T, Sunami E, Ota M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Sugihara K. Kusumoto T, et al. Clin Colorectal Cancer. 2018 Jun;17(2):e153-e161. doi: 10.1016/j.clcc.2017.10.015. Epub 2017 Nov 1. Clin Colorectal Cancer. 2018. PMID: 29249584 Free article. Clinical Trial.
84 results